Seven new investigators are joining the U.S. FDA's staff in India, raising the total of the American team assigned to handling regulatory issues tied to Indian generic drugmakers to 19. "Our presence in India allows us to better collaborate with our Indian regulatory counterparts and enables us to leverage our combined resources, harmonize science-based standards and increase regulatory capacity," according to a statement from the agency.

Full Story:
BioSpectrum Asia

Related Summaries